#BCMA
A small study of the first autologous BCMA-targeted CAR T-cell product for use in refractory primary #ITP has shown that the treatment resulted in rapid and sustained platelet recovery and durable drug-free complete remission lasting 15+ months: https://ow.ly/Ijwy510777n
November 17, 2026 at 4:00 PM
Clinical and Mechanistic Insights into Non-ICANS Neurotoxicity Following BCMA CAR T-Cell Therapy

www.neurology.org/doi/10.1212/...
Neurology® Journals
www.neurology.org
November 11, 2026 at 5:15 PM
$TPST 🤝

Tempest Therapeutics exclusively licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including lead BCMA/GPRC5D candidate TPST-4903, following initial Phase 1 results.

Market-relevant event

More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
November 13, 2026 at 9:49 PM
A new definition of cure in multiple myeloma? In this Hematology Highlights episode, Dr. Richter, breaks down the most impactful IMS 2026 data, including long-term remissions, earlier BCMA-directed therapy, and what's next for CAR T, bispecifics, CELMoDs, and trispecifics. https://bit.ly/4wGOqgx
November 13, 2026 at 8:11 PM
Such an important debate. The question fellows should hold onto: deep responses in smoldering myeloma only matter if they delay end-organ damage and improve survival, so infection risk from early BCMA-directed therapy has to be weighed against a disease some patients would never progress from.
November 11, 2026 at 10:48 PM
Such an important topic for anyone following CAR-T patients after discharge. The pattern we teach: bacterial infections cluster early, viral ones later, and hypogammaglobulinemia after BCMA targeting can last for months, so checking IgG belongs in long-term follow-up.
November 10, 2026 at 6:53 PM
Managing relapsed/refractory multiple myeloma requires balancing emerging treatment options with real-world patient needs. This complimentary CME series explores BCMA-directed therapies, treatment selection, access considerations, and strategies to support care:
clinical.med-iq.com/series/advan...
November 6, 2026 at 3:50 PM
【再発・難治性多発性骨髄腫で、12例中4例に奏効】
Modernaが、mRNA-2808の初期臨床データをASH年次総会で口頭発表する。再発・難治性多発性骨髄腫で12例中4例に奏効が見られた。Moderna、mRNA-2808の初期臨床データをASH年次総会で口頭発表へ──再発・難治性多発性骨髄腫で12例中4例に奏効
stellanews.life/technology/1...
Moderna、mRNA-2808の初期臨床データをASH年次総会で口頭発表へ──再発・難治性多発性骨髄腫で12例中4例に奏効
Moderna社は、BCMA・GPRC5D・FcRH5を標的とする多重mRNA治療薬「mRNA-2808」の第1/2相初期データを、2026年12月の米国血液学会年次総会で口頭発表すると発表した。
stellanews.life
November 7, 2026 at 9:57 AM
In this paper, the authors show that ramantamig, targeting BCMA and GPRC5D, killed more myeloma cells than single-target antibodies in laboratory studies. The findings support dual targeting to address tumor heterogeneity. Read it here: https://hsphere.pub/45939c
November 4, 2026 at 10:31 AM
#CGEM Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager,…

https://www.stocktitan.net/news/CGEM/cullinan-therapeutics-announces-presentations-for-cln-049-a-flt3-t-2d2pc4nssm6m.html?utm_source=stocktitan-bluesky&utm_medium=social
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Cullinan Therapeutics (Nasdaq: CGEM) will present CLN-049 and velinotamig research at the ASH Annual Meeting on December 12–15, 2026. Four posters will cover clinical and preclinical work.The CLN-049 Phase 1 abstract reports anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg in relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. Cullinan describes a favorable safety profile with double step-up dosing; updated dose-escalation results will be presented. Other posters cover an ongoing CLN-049 combination trial in newly diagnosed leukemia, a velinotamig trial in two autoimmune blood disorders, and preclinical findings on targeting cells involved in those disorders.
www.stocktitan.net
November 4, 2026 at 2:14 PM
IASO Bio's FUCASO Launch Event Marks a New Era in CAR-T Therapy in Southeast Asia#Singapore#CAR-T_therapy#IASO_Bio#FUCASO
IASO Bio's FUCASO Launch Event Marks a New Era in CAR-T Therapy in Southeast Asia
The launch of FUCASO marks the arrival of the first fully human BCMA CAR-T therapy in Southeast Asia, enhancing treatment options for multiple myeloma patients.
third-news.com
November 4, 2026 at 5:12 AM
France backs Talvey reimbursement but finds no added benefit despite updated evidence.
https://www.mattheneus.com/editorial/has-talvey-talquetamab-monotherapy-post-bcma-benefit-indirect-evidence-2026-09-09
#HTA #MAIC #EvidenceSynthesis
November 1, 2026 at 4:06 PM
BLA submitted to FDA for BCMA-directed, 2nd-generation bispecific antibody etentamig in R/R myeloma
Read more: sohoinsider.com/multiple-mye...
BLA submitted to FDA for BCMA-directed, 2nd-generation bispecific antibody etentamig in R/R myeloma
A Biologics License Application was submitted to the US Food and Drug Administration for the BCMA-directed, second-generation bispecific antibody etentamig for the treatment of relapsed or refractory…
sohoinsider.com
October 27, 2026 at 6:40 PM
AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.

buff.ly/x0KPnwv
AbbVie bids to join the BCMA crowd with etentamig
AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
buff.ly
October 28, 2026 at 2:30 PM
#$ABBV submitted a BLA for etentamig, a second-gen BCMA x CD3 bispecific antibody for relapsed or refractory multiple myeloma treatment.
October 27, 2026 at 1:03 PM
Eight fresh biopharma items: a reported $15bn Roche approach for Hansoh, GSK's vaccine-sales miss, AbbVie's BCMA entry with etentamig, an Amgen FDA warning letter, and new FDA draft guidance on personalized gene therapies.
https://openbionews.com/analysis/daily-bio-news-summary-2026-10-28/
Daily Bio News Summary — 2026-10-28: Deal desks and regulators set the tone | Data Analysis | OpenBio News
Eight fresh biopharma items from the last 30 days: a reported $15bn Roche approach for Hansoh, GSK
openbionews.com
October 29, 2026 at 2:01 AM
Promising advances in kidney transplant desensitization!

A phase 1 study reports that dual CD19/BCMA CAR-T therapy induced profound but transient B-cell depletion, ⬇️HLA sensitization, & enabled kidney transplantation in 2 highly sensitized patients

🔗DOI: 10.1056/NEJMoa2513428
October 27, 2026 at 4:09 PM
BCMA would like to extend our gratitude to our 2026 Conference Sustaining Sponsors! Thank you to EOS Lightmedia; Floreat Fine Art & Exhibit Logistics; Heritage BC; Hatlie Group; and Crocus Cultural Strategies.

To learn more about this year's sponsors, visit: museum.bc.ca/2026-bcma-co...
October 26, 2026 at 5:07 PM
To learn more about this year's conference sponsors, visit our website: museum.bc.ca/2026-bcma-co...
2026 Conference Sponsors - BCMA
Eos Lightmedia is the Accessibility Sponsor for the Redress theme of our virtual Joint Conference with Heritage BC. Their support helps us provide ASL translation to our sessions on May 18. Eos…
museum.bc.ca
October 26, 2026 at 5:07 PM
🩸 #MyélomeMultiple : une nouvelle thérapie par cellules #CAR_T 🧬 ciblant le #BCMA. atteint des taux de #Rémission élevés

▪️ 38 patients traités
▪️ Taux de réponse global : 100 %
▪️ Rémission complète : 79 %
▪️ Survie sans progression à 24 mois : 57 %

www.aerzteblatt.de/news/multipl...
Multiples Myelom: Neuartige CAR-T-Zelltherapie erzielt hohe Remissionsraten – Deutsches Ärzteblatt
www.aerzteblatt.de
October 24, 2026 at 9:33 AM
CAR-T therapy is opening a new frontier in autoimmune diseases and transplantation! 🧬

From CD19/BCMA targeting to faster manufacturing and in vivo approaches, the goal is shifting from immunosuppression toward an immune reset. Promising, but early!

#KidneyWk #CAR_T
October 22, 2026 at 3:22 PM
Worth remembering that talquetamab targets GPRC5D, not BCMA, which is why it stays an option after BCMA-directed therapy and why its toxicities (taste, skin and nail changes) differ from teclistamab's. Keeping BCMA and GPRC5D agents straight is what our knowledge graph was made for.
October 20, 2026 at 8:13 PM
BCMA would like to extend our gratitude to our 2026 Conference Supporters: Island Savings; Jim Cullen Consulting; Denim & Steel; CatalogIt; and Carr McLean.

To learn more about this year's conference sponsors, visit our website: museum.bc.ca/2026-bcma-co...

Thank you for your support!
October 20, 2026 at 5:03 PM
Explore a complimentary CME series focused on overcoming access challenges, applying emerging clinical data, and learning from real-world community experiences to help optimize care across the treatment journey: clinical.med-iq.com/series/advan...
October 20, 2026 at 3:53 PM